Barr gains majority of Pliva shares

Barr Pharmaceuticals would appear to have won the battle for Croatia's Pliva with its announcement that it has acquired more than 70 percent of the drug maker's stock. Barr had been in a bidding war with Actavis for control of Pliva. If Barr completes the deal, which seems likely, it will create the world's third largest generic drug maker.

- Here's the article from the International Herald Tribune

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.